Welcome to OncoDaily Weekly, your all-in-one roundup of this week’s oncology news, policy shifts, scientific advances, leadership moves and insightful stories from January 12 to 18.
How I Treat Cervical Cancer in 2026: OncoDaily Summit Livestreamed on Jan 24
On January 24, OncoDaily delivered a major educational milestone with the 9-hour livestreame of How I Treat Cervical Cancer in 2026 Summit – built as a practical, stage-by-stage roadmap spanning screening/staging through systemic therapy and designed explicitly for real-world decision-making. Delivered by 26 speakers from 5 continents, the post-event highlights captured the key takeaways and global voices that made this a clinician-facing “how-to,” not a theory session.
BGICC 2026: Partnership Coverage, On-Site Reporting, and Attendee Highlights
OncoDaily was at BGICC 2026 as an official partner – covering scientific content, on-site conversations, major partnerships and attendee-selected highlights. While Egyptian Cancer Society signed an MOU with IASLC during BGICC 2026, our team heard insights from the leaders in oncology and provided major scientific updates as they were being discussed onsite. Our “Not to Miss” coverage rolled out in two parts, helping readers scan the most practice-relevant threads without losing the nuance behind the data.
ASCO: Conquer Cancer 2026 Special Award Recipients Announced
ASCO and Conquer Cancer named 2026 Special Award recipients – honoring leaders across science, prevention, geriatric oncology, teaching and mentorship, humanitarian impact, and patient advocacy – highlighting the individuals shaping oncology beyond publications alone.
FDA and Regulation: New Guidance, New Metrics, and a 120-Year Milestone
The FDA released its 15th Annual New Drug Therapy Approvals report for 2025, providing the year’s official accounting of novel drug approvals and the agency’s evidence standards in practice, published an implementation roadmap for PreCheck, outlining how the agency plans to operationalize a new process intended to improve submission quality and reduce avoidable regulatory delays, a new guidance intended to speed multiple myeloma drug development, signaling a more deliberate push toward faster, clearer development pathways in hematologic malignancies that was celebrated by the community largely, and celebrated its 120th birthday which OncoDaily highlighted in a special editorial looking back at its historic significance in medicine.
Biotech and Pharma: Partnerships, Manufacturing, AI, and Deal Speculation
On the immuno-oncology side, Agenus closed a strategic collaboration with Zydus, bringing $141M in value and securing U.S. biologics manufacturing capacity to support development and potential scale-up of the botensilimab + balstilimab (BOT/BAL) program.
Bristol Myers Squibb drove two separate strategic moves: a partnership with Janux focused on tumor-activated T-cell engager technology, and a collaboration with Microsoft aimed at advancing AI-driven early lung cancer detection.
HER2 pipeline strategy was also in focus, with Boehringer Ingelheim and Jazz Pharmaceuticals highlighted for efforts advancing dual-therapy approaches in breast cancer.
Access Pathways and Global Approvals
A parallel cervical cancer elimination headline added global urgency: Karen Canfell highlighted a $13.1M investment aimed at accelerating cervical cancer elimination work across the Indo-Pacific.
Saudi Arabia’s SFDA approved Anktiva for bladder and lung cancer, marking a notable international regulatory expansion for the drug beyond its existing markets.
Ralph Lauren’s foundation committed major new funding toward cancer equity through a $25M national initiative, including a multi-year partnership with UChicago Medicine to expand prevention, diagnosis, treatment, navigation, and supportive services in underserved communities.
OncoDaily x CancerWorld
CancerWorld’s Issue #111 (January) was announced as live, featuring leadership-driven cover stories on Judy Habib (Chair of St. Jude’s board) and Dr. Hosam Abu Meri (Latvia’s Minister of Health and practicing gastroenterologist), framed around how leadership decisions directly translate into patient outcomes. Highlighting a year-in-review article CancerWorld reflected on the collaboration with OncoDaily and the shared focus on global oncology storytelling and impact.
OncoDaily TV: This Week’s Episodes
Karen Knudsen (CEO, Parker Institute for Cancer Immunotherapy) joined host Gevorg Tamamyan on OncoInfluencers to discuss leadership, strategy, and building real-world impact in cancer immunotherapy.
Alicia Zhou (CEO, Cancer Research Institute) explained CRI’s major infrastructure play: the CRI Discovery Engine, described as an AI-ready, open immunotherapy database built to address the reproducibility crisis and unlock “what worked” and “what failed” data at scale.
Emily Touloukian (CEO, Coastal Cancer Center) spoke to Jasmine Kamboj in the Empowering Oncologists series about what it truly takes to build and sustain a physician-led oncology practice.
Stay tuned with us as we continue to cover the latest advancements in oncology on daily bases.